(firstQuint)Randomized, Crossover Safety and Pharmacokinetics Study of PT010.

 This is a Phase I, single-center, randomized, double-blind, placebo-controlled, two period, ascending dose, cross-over study to assess safety and PK of two doses of PT010 in healthy adult subjects of Japanese descent.

 Safety and PK will be assessed following a single dose and during twice-daily (BID) chronic dosing for 7 days.

.

 Randomized, Crossover Safety and Pharmacokinetics Study of PT010@highlight

Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days.

